Table 3 Current and recently completed registered clinical trials, awaiting for results to be published
From: New developments in the molecular treatment of ichthyosis: review of the literature
Phase (ID) | Condition | Type of treatment | Approach | Participants (N) | Status | Reference |
|---|---|---|---|---|---|---|
I (NCT04549792) | Ichthyosis, not specified | Biological therapeutic | Antibody targeting IL-12/IL-23; Ustekinumab | 15 | Ongoing | |
II (NCT02113904) | NS | Biological therapeutic | Antibody targeting TNF-α; Adalimumab | 11 | Completed | |
II/III (NCT04244006) | NS | Biological therapeutic | Antibody targeting IL-4 and IL13; Dupilumab | 24 | Ongoing | |
II (NCT04697056) | Ichthyosis, not specified | Biological therapeutic | Antibody targeting IL-36 receptor; Imsidolimab | 24 | Ongoing | https://clinicaltrials.gov/ct2/show/NCT04697056?cond=ichthyosis&draw=2&rank=3 |
IV (NCT04996485) | Ichthyosis, children | Biological therapeutic | Antibodies targeting IL-17 (Secukinumab), IL-12/IL-23 (Ustekinumab), IL-4/IL-13 (Dupilumab) | 50 | Ongoing | https://clinicaltrials.gov/ct2/show/NCT04996485?cond=ichthyosis&draw=3&rank=6 |
I (NCT01428297) | NS | Small molecule | KLK7 and ELA2 inhibitor; BPR 277 | 12 | Completed | https://clinicaltrials.gov/ct2/show/NCT01428297?cond=netherton&draw=2&rank=7 |
III (NCT03445650) | SLS | Small molecule | Reactive Aldehyde Species (RASP) inhibitor; Reproxalap | 11 | Completed | |
II (NCT02402309) | SLS | Small molecule | Aldehyde binding small molecule; NS2 cream | 12 | Completed | https://clinicaltrials.gov/ct2/show/NCT02402309?cond=ichthyosis&draw=3&rank=23 |
I/II (NCT05211830) | NS | Small molecule | Topical application of a new developed protease inhibitor (SXR1096) | 20 | Ongoing | |
I/II (NCT04047732) | ARCI (TGM1) | Gene therapy | Non-integrating HSV-1 vector expressing TGM1 as a topical gel (KB105) | 6 | Ongoing | |
I (NCT01545323) | NS | Gene therapy | Grafting autologous epidermal sheets from genetically modified skin stem cells | 5 | Unknown |